MDRNA is a biotechnology company focused on the development and commercialization
of therapeutic products based on RNA interference (RNAi). We are building a
broad, flexible and cutting-edge...
Arrowhead Research Corporation is a publicly-traded nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy. Arrowhead is building value for...
Panomics is a privately-held life science company focused on parallel quantitative biology (PQB) a platform of reagents and products that enable the multiplex measurement of molecular events, such as...
We are rapidly gaining a reputation as the “go-to” firm that large pharmaceutical and biotechnology companies come to when encountering obstacles in developing new biological drugs. Our...
Article - 16 Sep 2009
RNA interference (RNAi) is a powerful strategy for suppressing gene expression in a sequence-specific manner. This strategy offers new potential opportunities for treating various diseases by...
News - 10 Feb 2009
Research and Markets has announced the addition of Jain PharmaBiotech's new
- Technologies, Markets and Companies" to their offering.
RNA interference (RNAi) or gene silencing...
News - 18 Oct 2013
Reportlinker.com announces that a new market research report is available in its catalogue: RNAi Technologies and Global...
News - 18 Nov 2014
Small pieces of synthetic RNA trigger a RNA interference (RNAi) response that holds great therapeutic potential to treat a number of diseases, especially cancer and pandemic viruses. The problem is...
News - 15 Oct 2008
a leading life science company and member of The RNAi Consortium (TRC), proudly
welcomes the Memorial Sloan-Kettering Cancer Center to the RNAi
Partnership Program. The...
News - 13 Aug 2009
Thermo Fisher Scientific
Inc. (NYSE: TMO), the world leader in serving science, announced today that
it has established a grant program to award life science researchers more than